baloxavir marboxil (xofluza) Report issue

Small molecule Approved FDA Priority Review FDA
AACT Drugs@FDA

Active Ingredient History

NOW
  • Now
Baloxavir marboxil, sold under the brand name Xofluza, is an antiviral medication for treatment of influenza A and influenza B. It was approved for medical use both in Japan and in the United States in 2018, and is taken as a single dose by mouth. It may reduce the duration of flu symptoms by about a day, but is prone to selection of resistant mutants that render it ineffectual.   Wikipedia

Chemistry

  • SMILES: OC1=C2N(C=CC1=O)N([C@@H]3COCCN3C2=O)[C@@H]4C5=CC=CC=C5SCC6=C(F)C(F)=CC=C46
  • InChIKey: FIDLLEYNNRGVFR-CTNGQTDRSA-N
  • Mol. Mass: 483.487
  • ALogP: 2.98
  • ChEMBL Molecules:
    baloxavir  
    baloxavir marboxil  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$55.3200 - $73.5449
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

baloxavir marboxil | s-033188

Organizations (12)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

Influenza, Human (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Coronavirus Infections (Phase 4)

Infections (Phase 4)

Influenza, Human (Phase 4)

Lymphoma (Phase 2)

Respiratory Tract Infections (Phase 4)

Transplants (Phase 4)

Virus Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue